Hepatitis C Virus
Conditions
Keywords
TMC435-TiDP16-C121, TMC435-C121, TMC435, TMC435350, Protease inhibitor, HCV, Hepatitis C
Brief summary
The purpose of this study is to compare the levels of TMC435 in the blood circulation after intake of 2 tablet formulations with the level of TMC435 in the blood circulation after intake of a capsule formulation. The trial will also evaluate levels of TMC435 in the blood circulation after intake of the capsule formulation fasted or following a meal.
Detailed description
This is a randomized (study drug assigned by chance), open-label (all people involved know the identity of the intervention), single dose, crossover (volunteers will receive different interventions sequentially during the trial) study in healthy volunteers. The trial will evaluate the levels of TMC435 in the blood circulation after a single dose of 150 mg TMC435 as a capsule formulation taken fasted (Treatment A) and following a meal (Treatment B). In addition, the study will evaluate the levels of TMC435 in the blood circulation after intake of a single dose of 150 mg TMC435 as 2 different tablet formulations (Treatments C and D). There will be a 14-day washout period between treatments and a 4-5 week follow-up at the end. Each volunteer will receive all four treatments. The main focus of the trial is the pharmacokinetic characteristics (how drugs are absorbed in the body, how they are distributed within the body and how they are removed from the body over time) of the different formulations. This evaluation requires multiple blood samples from Day 1 through 72 hours after dosing. Safety assessments (lab work, blood pressure, pulse and electrocardiogram) will follow a different schedule and are measured on Day -1 (day prior to taking first dose of drug), Day 1 (day of first dosing) and/or Day 4 of each treatment period, and 4 weeks after the last treatment. Each volunteer will receive 4 treatments, about 14 days apart from each other. Each treatment consists of one single dose of 150 mg TMC435.
Interventions
DRUGTMC435
Sponsors
Tibotec Pharmaceuticals, Ireland
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Non-smoker for at least 3 months * Body Mass Index of 18.0 to 30.0 kg/m2 * Healthy based on a medical evaluation including medical history, physical examination, blood tests and electrocardiogram
Exclusion criteria
* Infection with Hepatitis A, B or C virus * Infection with the human immunodeficiency virus (HIV) * Women who are pregnant or breastfeeding * History of, or any current medical condition which could impact the safety of the participant in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate and extent of absorption of TMC435 following administration of the tablet vs the capsule formulations and rate and extent of absorption of TMC435 following administration of the capsule formulation fasted or with food | Measured over a period of 4 consecutive days (Day1-Day4) per treatment. Treatments (4) are 14 days apart from each other. During 1st day of each treatment, 10 blood samples for determination of pharmacokinetic characteristics are taken. |
Secondary
| Measure | Time frame |
|---|---|
| Safety and tolerability following administration of single doses of 150 mg TMC435 | AEs: continuously: laboratory, vital signs and ECG parameters: 3 visits per treatment, for 4 treatment periods |
Outcome results
None listed